Comprehensive Library Of Resveratrol News

Subscribe to our newsletter to receive email notifications when new articles are posted.


  • Longevinex® Favorably Improves Cholesterol

    November 9, 2010: by Bill Sardi

    Longevinex® Produces Heart-Healthiest Laboratory Rats In The World; Nutriceutical Has Profound Effect Upon Cholesterol-Fed Animals.

    Las Vegas, NV (November 8, 2010) – According to the latest published research, the heart-healthiest laboratory animals in the world are taking Longevinex®, a red wine pill dietary supplement.

    Researchers gave cholesterol-fed rabbits Longevinex®, a proprietary blend of red wine molecules (resveratrol, quercetin, ferulic acid) plus rice bran IP6 and vitamin D3, and found this dietary supplement:

    • More than halves circulating total cholesterol among cholesterol-fed animals.
    • Cuts arterial plaque (the stuff that sticks to artery walls) by more than half.
    • Reduces the area of damage to the heart following heart attack by 30%-40%, thus sparing the animal’s life.
    • Improves the heart-pumping action of the heart following a heart attack.
    • Improves blood flow in both the aorta (first blood vessel outside the heart) and in the four coronary arteries that supply the heart with oxygenated blood, following an intentionally-induced heart attack.

    Rabbit owners can feed their pets Longevinex®, knowing they will be the heart-healthiest animals in the world. The study, entitled “Reduction of blood cholesterol and ischemic injury in the hypercholesteromic rabbit with modified resveratrol, Longevinex®,” was published in the journal of Molecular & Cellular Biochemistry. To learn more about Longevinex®, click here. #### © 2010 Resveratrol Partners LLC, not for posting on other websites.

    Heart-Healthy Effects of Longevinex® in Cholesterol-Fed Laboratory Animals

    Molecular & Cellular Biochemistry 2010 Nov 4 online

    Measured Parameter

    Non-cholesterol-fed

    Cholesterol-fed + Longevinex®

    Circulating total cholesterol at 32 weeks

    26

    12.5

    Arterial plaque

    84

    40

    Blood flow in coronary arteries 120 minutes following heart attack in
    6-month old animals

    48

    60

    Blood flow in aorta (first blood vessel outside the heart) 120-minutes following heart attack in 6-month old animals

    17

    33

    Heart pumping action
    2 hours following heart attack in 6-month old animals

    56

    69

    Commentary: Longevinex® Lowers Cholesterol, Improves Circulation in Cholesterol-Fed Rabbits

    Commentary: The recently published study in Molecular & Cellular Biochemistry showing a resveratrol-based nutriceutical (Longevinex®, pronounced long-jev-in-ex)) significantly reduces circulating levels of cholesterol and improved blood circulation in cholesterol-fed rabbits is noteworthy, but probably for reasons other than what most health-minded readers would assume.

    Circulating cholesterol levels are not associated with coronary artery disease in healthy individuals, despite what you may have read elsewhere. But the Longevinex® trial IS significant because, in humans, the accumulation of stored iron and copper in the liver leads to fatty liver, a condition that is found in about 35% of American adults. Longevinex® is a matrix of mineral-chelating (key-lay-ting) small molecules derived from botanical sources that is intended to control metallic minerals such as iron and copper, as well as calcium.

    A very recent study shows as iron accumulates in the liver with advancing age, several enzymes involved in the natural synthesis of cholesterol are activated in the liver. There is, however, no significant relationship between iron levels in the liver and circulating cholesterol (which is what doctors measure). This means that this Longevinex® study is more pertinent in heading off or reversal of fatty liver than it is any alleged prevention of cholesterol plaque buildup in arteries.

    This does not mean that Longevinex® provides no potential benefits for consumers interested in heart health. In fact, Longevinex® is the first branded resveratrol pill to exhibit cardio-protection, that is, protects the heart from damage during a heart attack (animal study), thus averting sudden cardiac death. Resveratrol, a key ingredient in Longevinex®, is also known to thin the blood like aspirin, preventing clots that may block circulation of oxygenated blood to the heart. Resveratrol has been shown to release, before a heart attack, three protective molecules, adenosine, nitric oxide and heme oxygenase, that are otherwise only produced following a heart attack.

    Not a real-world test

    If it can be assumed that animal studies are reflective of what goes on in humans, then this study is of some value. However, it is not a real world test. The animals are engorged with a high-cholesterol diet, something that is not particularly reflective of human practice unless one eats a lot of cholesterol-rich eggs every day. Only about 20% of the cholesterol in the human body comes from the diet, the rest is made naturally in the liver. Dietary cholesterol has little impact upon circulating cholesterol levels. Where the modern world went wrong was when refined sugar, not cholesterol, became widely available and laced into all manner of processed foods (bread, salad dressings, ketchup, soups, etc.).

    Humans will some day realize they have been conned about cholesterol in order to sell pills. In a healthy state, the liver naturally produces cholesterol. Cholesterol is required for sex drive and procreation since sex hormones (testosterone, estrogen) are synthesized from cholesterol. Cholesterol also transports antioxidants like vitamin E and carotenoids (beta carotene, lutein, lycopene) to tissues, and is needed for mood maintenance. Too-low cholesterol increases the risk for mental depression.

    Furthermore, cholesterol is not the primary cause of coronary artery disease or arterial plaque. Only about 3% of plaque found in human arteries is cholesterol, while 50% is calcium. When the French Paradox was first described by Dr. Serge Renaud in the early 1990s, the paradox was that the French consume a relatively high-fat diet and have a bit higher cholesterol levels than North Americans, yet their mortality rate due to coronary artery disease is ~90 per 100,000 versus 240 per 100,000 in the U.S.

    But then again, maybe it wasn’t cholesterol that causes coronary artery disease at all! There are a number of studies which now indicate high cholesterol is protective and healthy.

    An earlier published animal study showed that resveratrol suppresses arterial plaque without affecting blood cholesterol levels. It is important for consumers to realize resveratrol may be beneficial without affecting cholesterol levels

    Please direct your questions regarding Longevinex and resveratrol to info@longevinex.com Bill Sardi, © 2010, Resveratrol Partners LLC


    Molecular & Cellular Biochemistry 2010 Nov 4. [Epub ahead of print]

    Reduction of blood cholesterol and ischemic injury in the hypercholesteromic rabbits with modified resveratrol, Longevinex®

    Juhaz B, Das DK, Kertesz A, Juhasz A, Gesztelyi R, Varga B.

    Department of Pharmaceutical Sciences, University of Debrecen, Debrecen, Hungary.

    Abstract

    The present study examined the efficacy of using Longevinex, a commercially available resveratrol formulation, to lower blood cholesterol in hypercholesteromic rabbits. New Zealand white rabbits were randomly divided into two groups (n = 6 per group), one group was given high cholesterol diet for 3 months while the other group fed regular diet served as control. The high cholesterol diet fed group was further subdivided into two groups (n = 6 per group), one group was given Longevinex resveratrol while the other group given vehicle only served as control. Longevinex was given by gavaging up to a period of 6 months. Longevinex-treated rabbits exhibited lowering of plasma cholesterol level. Inhibition of arterial plaque formation was noticed even after 1 month. Longevinex-treated hearts demonstrated improved ventricular recovery when isolated working hearts were subjected to 30 min of ischemia followed by 2 h of reperfusion. Aortic flow and developed pressure during post-ischemic reperfusion period were significantly higher for the Longevinex-treated hearts compared to those in control group of hearts. Myocardial infarct size was also lower in the treated group compared to that for the untreated group. These results indicate cholesterol-lowering ability of Longevinex, which appears to reflect in its ability to protect the hypercholesteromic hearts from ischemic reperfusion injury. PMID: 21052791

    Share

Leave a Reply


In order to submit your comment please complete the calculation below:


Time limit is exhausted. Please reload CAPTCHA.